Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meeting.

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced a new study in Dermatology and Therapy that analyzed the independent performance of its DecisionDx®-SCC test.

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript

The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023. “2023 was another exceptional year, with strong top-line growth and test report volume growth, driven in large part by consistent execution by the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “I.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Beyond analysts' top -and-bottom-line estimates for Castle Biosciences, Inc. (CSTL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AJCC8--Castle announced a study showing DecisionDx-Melanoma provided significantly better risk stratification than AJCC8 staging in stage I melanoma.

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced it will release its financial results for Q4 & year ended Dec. 31, 2023 after the close of market on Feb. 28, 2024.

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New study finds using Castle's DecisionDx-SCC test to guide ART decisions for SCC patients could result in substantial Medicare healthcare savings.

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data across its dermatologic portfolio of GEP tests at the 2024 Winter Clinical Dermatology Conference - Hawaii.

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2023. “Our fourth quarter was the culmination of an exceptional year, where we delivered consistent, strong growth in both revenue and test volume,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

The mean of analysts' price targets for Castle Biosciences, Inc. (CSTL) points to a 67% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma.

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting.

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has been named a Houston Chronicle Top Workplace for the third year in a row.

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major depressive disorder (MDD).

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.

Castle Biosciences to Present at Upcoming Investor Conferences

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Catherine Schulte - Baird Mason Carrico - Stephens Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today's call is being recorded.

Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced data from an exploratory study investigating the potential for developing a test that would complement DecisionDx®-UM.

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data related to its inflammatory skin disease pipeline program.

Early Discovery Data Shows Ability of Castle Biosciences' Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle today announced its financial results for the third quarter and nine months ended September 30, 2023.

Castle Biosciences Reports Third Quarter 2023 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle will highlight the risk stratification provided by its TissueCypher® Barrett's Esophagus test through two posters at ACG 2023.

Castle Biosciences to Present New Data on its TissueCypher® Barrett's Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2023, after the close of market on Thursday, Nov. 2, 2023.

News for Castle Biosciences Inc Stock (CSTL)